Rhonda Knudsen is a business operations management professional with more than 25 years of experience in the life science, medical device, and technology sectors. She leads the finance, human resources, and business administration functions for Bonum Therapeutics. She joined Good Therapeutics in 2021 and transitioned to Bonum Therapeutics after the acquisition by Roche in 2022. […]
Dr. Linda Liang brings over 20 years of biologics discovery and development experience. She joined Bonum Therapeutics in 2023. Prior to Bonum, she held senior positions in antibody discovery and early development at Pionyr Immunotherapeutics, Bristol-Myers Squibb, Merck, Schering-Plough, and Organon where she advanced programs in immuno-oncology, autoimmune and inflammatory diseases, and metabolic diseases. Linda […]
Dr. David Bienvenue leverages over 20 years of protein development experience to advance Bonum’s candidates towards the clinic. He joined Good Therapeutics in 2021 then transitioned to Bonum Therapeutics after the acquisition by Roche in 2022. He previously served as Vice President of Protein Sciences, Analytical and Process Development at Aptevo Therapeutics. He led the […]
Dr. Justin Killebrew brings over 15 years of research and drug discovery experience in the areas of oncology and immunology. He joined Good Therapeutics in 2018 and transitioned to Bonum Therapeutics following the acquisition by Roche in 2022. Before joining Good, he was Director of Discovery Biology at Silverback Therapeutics, where he oversaw in vitro […]
Cindy Yee brings over 25 years of drug discovery & development, partnership and portfolio experience. She leads preclinical development, portfolio, project & alliance management. She joined Good Therapeutics in 2021 and transitioned to Bonum Therapeutics after the acquisition by Roche in 2022. Previously, she served as Director of Alliances at BeiGene where she led implementation of global strategic […]
Dr. Neela Patel is a scientist and business development executive with more than 25 years of leadership experience in drug discovery & development, project & portfolio management, and pipeline development through external innovation. Prior to Bonum, as Chief Business Development Officer at Good Therapeutics she co-led the Roche transaction and spinout of Bonum. Previously, as […]
Dr. Diane Hollenbaugh is a drug discovery scientist and executive with more than 25 years of experience in biologicals research and discovery, and early development. She joined Good Therapeutics in 2019 and transitioned to Bonum Therapeutics following the acquisition by Roche in 2022. Prior to Good, she was Executive Director, Immuno-oncology Discovery at AbbVie where […]
Dr. John Mulligan is a scientist and executive with 30 years of experience in research management, drug discovery, technology innovation and company formation. He was the Founder and CEO of Good Therapeutics until it was acquired by Roche in 2022. Prior to Good he founded Glycostasis, where he invented a glucose-responsive insulin technology and sold […]